Latest News
- Nanobiotix Starts Clinical Trial with Lead Product NBTXR3
- Nanobiotix announces changes to its Non Executive Board
- Nanobiotix welcomes Dr Bernd Mühlenweg as Head of Business Development
- Launch of the NanomedTV
- Nanobiotix welcomes Laurent Condomine on board
- Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round
- Nanobiotix reports ‘proof of concept’ for its nanoparticles in treating glioblastoma multiforme (brain cancer)
- Nanobiotix enters into collaboration with “SonoDrugs” consortium
- Nanobiotix announces issue of European patent protecting its nanoXray anticancer platform
- Nanobiotix and BiotechCorp announce initial focus of their collaboration